Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

• E-WE Thrombin- Dose 1 (Drug), also known as AB002- Dose 1: Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
• E-WE Thrombin- Dose 2 (Drug), also known as AB002- Dose 2: Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
• E-WE Thrombin- Dose 3 (Drug), also known as AB002- Dose 3: Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
• E-WE Thrombin- Dose 4 (Drug), also known as AB002- Dose 4: Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
• Placebo (Other): Participants received a single intravenous dose of placebo.

Primary outcomes

• The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. [one month]: TEAEs will be determined by symptom driven physical examinations that can include assessment of the skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.
• The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed. [two days]: Body temperature will be measured in degrees Celsius. Clinically significant changes in body temperature are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed. [two days]: Respiratory rate will be measured in breaths per minute. Clinically significant changes in respiratory rate are determined by the PI.
• The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed. [two days]: Systolic and diastolic blood pressure will be measured in mmHg. Clinically significant changes in systolic and diastolic blood pressure are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed. [two days]: Heart rate will be measured in beats per minute. Clinically significant changes in heart rate are determined by the PI or designee.
• The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment. [two days]: 12-lead electrocardiogram measurement. Abnormal electrocardiograms are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. [one month]: Plasma aPTT will be measured in seconds. Clinically significant changes in aPTT are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. [one month]: Prothrombin time will be measured in seconds. Clinically significant changes in prothrombin time are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. [one month]: Thrombin time will be measured in seconds. Clinically significant changes in thrombin time are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. [one month]: Plasma fibrinogen levels will be measured in mg/dL. Clinically significant changes in plasma fibrinogen levels are determined by the PI or designee.
• The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment. [two days]: Injection site reaction assessment (pain, tenderness, erythema/ redness, and induration/ swelling.
• The Number of Subjects That Develop Treatment-related Immunogenicity. [one month]: Immunogenicity measured by plasma anti-drug antibodies.
• The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed. [two days]: BUN levels in the blood will be measured in mg/dL. Clinically significant changes in BUN are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Bilirubin (total and direct) levels in the blood will be measured in mg/dL. Clinically significant changes in total and direct bilirubin levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Alkaline phosphatase levels in the blood will be measured in U/L. Clinically significant changes in alkaline phosphatase levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: AST levels in the blood will be measured in U/L. Clinically significant changes in AST levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: ALT levels in the blood will be measured in U/L. Clinically significant changes in ALT levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: LDH levels in the blood will be measured in U/L. Clinically significant changes in LDH levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days.]: Albumin levels in the blood will be measured in g/dL. Clinically significant changes in albumin levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Sodium levels will be measured in mEq/L. Clinically significant changes in sodium levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Potassium levels will be measured in mEq/L. Clinically significant changes in potassium levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Chloride levels will be measured in mEq/L. Clinically significant changes in chloride levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Bicarbonate levels will be measured in mEq/L. Clinically significant changes in bicarbonate levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Blood glucose levels will be measured in mg/dL. Clinically significant changes in blood glucose levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. [two days]: Creatinine levels will be measured in mg/dL. Clinically significant changes in creatinine levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days]: Hemoglobin levels will be measured in g/dL. Clinically significant changes in hemoglobin levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days]: Hematocrit levels will be measured in %. Clinically significant changes in hematocrit levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days.]: Total leukocyte counts will be measured in 10˄3/uL. Clinically significant changes in leukocyte counts are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days.]: Differential leukocyte counts will be measured in %. Clinically significant changes in differential leukocyte counts are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days]: Red blood cell count will be measured in 10˄6/uL. Clinically significant changes in red blood cell counts are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. [two days]: Platelet count will be measured in 10˄3/uL. Clinically significant changes in platelet counts are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: pH of the urine will be measured. Clinically significant changes in urine pH are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Specific gravity of the urine will be evaluated. Clinically significant changes in specific gravity are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Protein levels in the urine will be evaluated. Clinically significant changes in protein levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Glucose levels in the urine will be evaluated. Clinically significant changes in urine glucose are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Ketone levels in the urine will be evaluated. Clinically significant changes in urine ketone levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Bilirubin levels in the urine will be evaluated. Clinically significant changes in urine bilirubin levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Blood levels in the urine will be evaluated. Clinically significant changes in urine blood levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Nitrite levels in the urine will be evaluated. Clinically significant changes in urine nitrite levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Urobilinogen levels in the urine will be evaluated. Clinically significant changes in urine urobilinogen levels are determined by the PI or designee.
• The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel. [two days]: Leukocyte esterase levels in the urine will be evaluated. Clinically significant changes in urine leukocyte esterase levels are determined by the PI or designee.

Secondary outcomes

• The Effect of a Single Intravenous Dose of E-WE Thrombin on Generation of Activated Protein C- Protein C Inhibitor Complexes (APC-PCI). [Predose, 0.08, 0.25, 0.5, 1, 2, 4, and 24h post-dose]: Plasma APC-PCI levels will be measured in ng/mL.

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Inclusion Criteria:

1. Healthy, adult, male and/or female (females of non-childbearing potential only), 18 to 55 years of age, inclusive, at screening.
2. Continuous non-smoker, who has not used nicotine-containing products for at least 3 months prior to dosing, based on subject self-reporting.
3. Body mass index (BMI) ≥ 18 and < 29 (kg/m2) at screening and weight between 50 and 125 kg (inclusive) at screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms, as deemed by the PI or designee.
5. A female must be of non childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to dosing:

   * hysteroscopic sterilization;
   * bilateral tubal ligation or bilateral salpingectomy;
   * hysterectomy;
   * bilateral oophorectomy. or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.
6. A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to dosing of study drug. A male who has been vasectomized less than 4 months prior to dosing must follow the same restrictions as a non vasectomized male).
7. If male, must agree to not donate sperm from dosing until 90 days after dosing.
8. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past 2 years prior to dosing.
5. Consumes 3 units or more of alcohol per day (e.g., 1 unit is equivalent to 240 mL of wine, 1 bottle of beer \[12 oz.\], or 1 shot of liquor \[1 oz.\]).
6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug and excipients or related compounds.
7. History or presence of a disease or disorder, acquired or inherited, that is active, or could be reasonably expected to become active during the study, including but not limited to:

   * Hypersensitivity to ß-lactam / penicillin derivatives;
   * Bleeding and blood coagulation disorders, including stroke, hemophilias, thrombophilias, or heparin-induced thrombocytopenia;
   * Ischemic disorders, including stroke, heart attack, coronary artery disease;
   * Gastrointestinal disorders, including gastrointestinal bleeds, gallstones, ulcers, diseases or dysfunction of the liver and excluding appendectomy and/or cholecystectomy;
   * Genitourinary disorders, including renal disease;
   * Cardiovascular disorders, including aneurysms, vasculitis;
   * All conditions that are associated with taking medications for pain;
   * Infection of any organ or system within 30 days of dosing;
   * Malignant and cancerous neoplasms of any organ or system;
   * Psychiatric and behavioral disorders;
   * A clinically significant hematological disorder of any type;
   * Inflammation and inflammatory diseases of any organ system.
8. Females of childbearing potential.
9. Females who are pregnant or who are lactating.
10. Positive urine drug or alcohol results at screening or check in.
11. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
12. Supine blood pressure is less than 90/50 mmHg or greater than 140/90 mmHg at screening.
13. Supine heart rate is lower than 40 bpm or higher than 99 bpm at screening.
14. QTcF interval > 450 msec for males or > 460 msec for females, or history of prolonged QT syndrome at screening.
15. Estimated creatinine clearance < 90 mL/minutes at screening using the Cockcroft Gault estimation.
16. Unable to refrain from or anticipates the use of:

    * Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to dosing and throughout the study.
    * Any oral or injectable anticoagulant (e.g., warfarin, heparin, low molecular weight heparin, etc.), coagulants (aprotinin, tranexamic acid, epsilon-aminocaproic acid, and aminomethylbenzoic acid), anti-platelet (e.g., clopidogrel), nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetylsalicylic acid (ASA) beginning approximately 10 days prior to dosing and throughout the study.
    * Any drugs known to be significant inducers of cytochrome P-450 enzymes and/or P glycoprotein, including St. John's Wort, for 28 days prior to dosing and throughout the study.

    Appropriate sources (e.g., Flockhart TableTM) will be consulted to confirm lack of pharmacokinetic/ pharmacodynamic interaction with study medication. Acetaminophen (up to 2 g per 24 hour period) or any other treatment of an adverse event, drug related or not, and considered appropriate and allowable by the PI or designee may be permitted after dosing.
17. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 30 days prior to dosing and throughout the study.
18. Has participated in strenuous exercise or physical activity within 72 hours prior to Day 1, unless deemed acceptable by the PI or designee.
19. Donation of blood or significant blood loss within 56 days prior to dosing.
20. Plasma donation within 7 days prior to dosing.
21. Has been hospitalized within 2 months of Day -1.
22. Participation in another clinical study within 30 days prior to dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
23. Surgery within the past 90 days prior to dosing which in the opinion of the PI or designee is clinically relevant.
24. Presence of any scars, or tattoos which may obscure the injection site, as deemed by PI or designee.
25. Any condition or circumstance, in the opinion of the PI or designee, which may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety.

Participant flow

Outcome results

• The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 3; Placebo 1
• The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects That Develop Treatment-related Immunogenicity. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. (Primary), Count of participants, Participants: E-WE Thrombin Dose 1 0; E-WE Thrombin Dose 2 0; E-WE Thrombin Dose 3 0; E-WE Thrombin Dose 4 0; Placebo 0
• 22 more outcome measures not shown.

Adverse events

Time frame: Adverse events were recorded from subject check-in through follow up which occurred on Day 28.

Other adverse events by term

• Results publication: Tucker EI, Verbout NG, Markway BD, Wallisch M, Lorentz CU, Hinds MT, Shatzel JJ, Pelc LA, Wood DC, McCarty OJT, Di Cera E, Gruber A. The protein C activator AB002 rapidly interrupts thrombus development in baboons. Blood. 2020 Feb 27;135(9):689-699. doi: 10.1182/blood.2019002771. PMID 31977000

• Statistical Analysis Plan (PDF, 2018-07-25)
• Study Protocol (PDF, 2018-05-14)

• Danielle Armas, MD, Principal investigator, Celerion